Table 1

RP11-273G15.2 expression levels in patients with SLE with or without clinical features

SLEClinical features presentSLEClinical features absentP value
NMedian (IQR, 10−3)NMedian (IQR, 10−3)
Clinical features at sample collection
 Vasculitis3/51 (5.88%)2.81 (2.62, 2.98)48/51 (94.12%)0.73 (0.38, 1.27)0.004**
 Malar rash17/51 (33.33%)1.16 (0.72, 1.87)34/51 (66.67%)0.67 (0.35, 1.21)0.050
 Discoid rash9/51 (17.65%)0.59 (0.34, 1.46)42/51 (82.35%)0.76 (0.50, 1.32)0.952
 Oral ulcer1/51 (1.96%)3.28 (3.28, 3.28)50/51 (98.04%)0.74 (0.44, 1.32)0.078
 Thrombocytopenia8/51 (15.69%)1.55 (0.95, 2.93)43/51 (84.31%)0.72 (0.35, 1.27)0.010*
 Lymphocytopenia22/51 (43.14%)1.18 (0.76, 1.93)29/51 (56.86%)0.59 (0.37, 0.99)0.007**
 Anaemia32/51 (62.75%)0.83 (0.54, 1.79)19/51 (37.25%)0.60 (0.36, 1.32)0.250
 Leukocytopenia11/51 (21.57%)1.81 (1.18, 2.20)40/51 (78.43%)0.73 (0.35, 1.16)0.006**
 Renal involvement24/51 (47.06%)0.73 (0.44, 1.14)27/51 (52.94%)0.99 (0.45, 1.58)0.533
 Arthritis8/51 (15.69%)1.21 (0.59, 1.38)43/51 (84.31%)0.73 (0.38, 1.51)0.452
 Serositis9/51 (17.65%)0.73 (0.52, 1.90)42/51 (82.35%)0.76 (0.44, 1.27)0.584
 Neuropsychiatric3/51 (5.88%)0.78 (0.65, 0.92)48/51 (94.12%)0.74 (0.38, 1.58)0.865
 Photosensitivity4/51 (7.84%)1.15 (0.64, 1.54)47/51 (92.16%)0.73 (0.44, 1.39)0.853
Laboratory test
 C3<0.9 g/L13/50 (26.00%)0.74 (0.57, 1.11)37/50 (74.00%)0.73 (0.39, 1.46)0.799
 C4<0.1 g/L31/50 (62.00%)0.73 (0.43, 1.13)19/50 (38.00%)1.20 (0.44, 1.85)0.219
 ANA51/51 (100.00%)0.74 (0.44, 1.39)0/51 (0.00%)
 Anti-dsDNA38/51 (74.51%)0.94 (0.58, 1.51)13/51 (25.49%)0.52 (0.39, 1.20)0.300
 Anti-Sm12/50 (24.00%)1.38 (1.07, 2.20)38/50 (76.00%)0.73 (0.35, 1.18)0.008**
 Anti-U1RNP23/50 (46.00%)1.20 (0.60, 1.84)27/50 (54.00%)0.72 (0.29, 1.08)0.009**
 Anti-SSA-Ro5228/50 (56.00%)0.76 (0.44, 1.26)22/50 (44.00%)0.91 (0.58, 1.75)0.584
 Anti-SSA-Ro6027/50 (54.00%)0.99 (0.50, 1.38)23/50 (46.00%)0.72 (0.45, 1.51)0.514
 Anti-SS-B (La)8/50 (16.00%)0.76 (0.36, 1.02)42/50 (84.00%)0.81 (0.52, 1.58)0.427
 Anti-ribosomal P protein16/51 (31.37%)1.56 (0.76, 2.62)35/51 (68.63%)0.61 (0.35, 1.10)0.004**
 Anti-histone13/51 (25.49%)1.09 (0.33, 1.33)38/51 (74.51%)0.74 (0.50, 1.38)0.931
 Anti-nucleosome33/51 (64.71%)0.73 (0.39, 1.33)18/51 (35.29%)0.94 (0.50, 1.38)0.783
 ESR>20 mm/h(woman), >15 mm/h (man)43/51 (84.31%)0.74 (0.44, 1.58)8/51 (15.69%)0.67 (0.40, 1.25)0.533
  • P values were for comparing RP11-273G15.2 levels in patients with or without clinical features by Mann-Whitney Wilcoxon U test, *p<0.05; **p<0.01;***p<0.001; ****p<0.0001.

  • ANA, antinuclear antibody; C3, complement 3; C4, complement 4; ESR, erythrocyte sedimentation rate; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; U1RNP, U1 ribonucleoprotein.